We observed that both “Selumetinib and Pimasertib” were highly effective in CD15/FUT4-high expressing CRC cells with intrinsic resistance to cetuximab or bevacizumab, as compared to those with CD15/FUT4-low expression one (Fig. 4c). Here, FUT4 is linked to colorectal carcinoma.